L1 1 S US 20060241102/PN

FILE 'REGISTRY' ENTERED AT 08:41:48 ON 15 OCT 2009
L2 1 S 9001-66-5/RN
SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:42:02 ON 15 OCT 2009
L3 1 S 56296-78-7/RN



SET NOTICE 1 DISPLAY
SET NOTICE LOGIN DISPLAY

FILE 'REGISTRY' ENTERED AT 08:42:26 ON 15 OCT 2009
E KW6002/CN
SET EXPAND CONTINUOUS
L4 1 S KW 6002/CN
E KW 6002/CN
L5 1 S E15

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 155270-99-8 REGISTRY
ED Entered STN: 24 May 1994
CN 1H-Purine-2,6-dione, 8-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-
3,7-dihydro-7-methyl- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Purine-2,6-dione, 8-[2-(3,4-dimethoxyphenyl)ethenyl]-1,3-diethyl-3,7-
dihydro-7-methyl-, (E)-
OTHER NAMES:
CN Istradefylline
CN KW 6002
FS STEREOSEARCH
MF C20 H24 N4 O4
CI COM
SR CA
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, BIOSIS, BIOTECHNO, CA,
CAPLUS, CASREACT, CBNB, CHEMCATS, CIN, EMBASE, IMSPATENTS, IMSRESEARCH,
IPA, MEDLINE, MRCK*, PHAR, PROMT, PROUSDDR, RTECS*, SYNTHLINE,
TOXCENTER, USAN, USPAT2, USPATFULL
(*File contains numerically searchable property data)

Double bond geometry as shown.



E FLUOXETINE/CN
L6 1 S E27

L6 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2009 ACS on STN
RN 54910-89-3 REGISTRY
ED Entered STN: 16 Nov 1984
CN Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN Benzenepropanamine, N-methyl-γ-[4-(trifluoromethyl)phenoxy]-, (±)-
OTHER NAMES:
CN (±)-Fluoxetine
CN (±)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine
CN 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
CN Deprex
CN dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine
CN Fluoxetin Ratiopharm
CN Fluoxetine
CN Fluoxin
CN Fluval
CN N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine
CN Nikomed
CN NSC 283480
CN Symbiax
DR 57226-07-0, 52341-67-0
MF C17 H18 F3 N O
CI COM
LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, AQUIRE, BEILSTEIN*,
BIOSIS, BIOTECHNO, CA, CABA, CAPLUS, CASREACT, CBNB, CHEMCATS,
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DRUGU, EMBASE, HSDB*,
IFICDB, IFIPAT, IFIUDB, IMSDRUGNEWS, IMSPATENTS, IMSPRODUCT,
IMSRESEARCH, IPA, MEDLINE, MRCK*, MSDS-OHS, PHAR, PROMT, PROUSDDR, PS,
RTECS*, SPECINFO, SYNTHLINE, TOXCENTER, USAN, USPAT2, USPATFULL, VETU
(*File contains numerically searchable property data)
Other Sources: WHO



FILE 'HCAPLUS' ENTERED AT 08:43:33 ON 15 OCT 2009

FILE 'HCAPLUS' ENTERED AT 08:44:03 ON 15 OCT 2009
L7 595 S L3
L8 106 S L5
L9 5344 S L6
L10 2 S L7 AND L8

L10 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Methods and compositions for the treatment of neurodegenerative disorders
ACCESSION NUMBER: 2008:1337969 HCAPLUS Full-text
DOCUMENT NUMBER: 149:525459
TITLE: Methods and compositions for the treatment of neurodegenerative disorders
INVENTOR(S): Jin, Xiaowei; Staunton, Jane; Macdonald, Douglas;
Dong, Hualing; Kifle, Lydia
PATENT ASSIGNEE(S): Combinatorx, Incorporated, USA; CHDI, Inc.
SOURCE: PCT Int. Appl., 123pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008133884	A2	20081106	WO 2008-US5194	20080423

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,

TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
PRIORITY APPLN. INFO.: US 2007-925753P P 20070423
US 2007-958774P P 20070709

L10 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Medicinal compositions containing adenosine A2A receptor antagonists and
other antidepressants
ACCESSION NUMBER: 2005:99358 HCAPLUS Full-text
DOCUMENT NUMBER: 142:162694
TITLE: Medicinal compositions containing adenosine A2A
receptor antagonists and other antidepressants
INVENTOR(S): Kase, Hiroshi; Kobayashi, Minoru; Shiozaki, Shizuo;
Mori, Akihisa; Seno, Naoki
PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009444	A1	20050203	WO 2004-JP10758	20040722

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

CA 2533117 A1 20050203 CA 2004-2533117
20040722
EP 1655029 A1 20060510 EP 2004-748023
20040722
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
US 20060241102 A1 20061026 US 2006-565239
20060119
NO 2006000958 A 20060425 NO 2006-958
20060227
PRIORITY APPLN. INFO.: JP 2003-201549 A
20030725
WO 2004-JP10758 W
20040722
IC ICM A61K031-52
ICS A61K031-137; A61K031-335; A61K031-343; A61K031-36; A61K031-
38;
A61K031-381; A61K031-435; A61K031-496; A61K031-5375; A61K031-
55;
A61K031-553; A61P025-24
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1
IT 56296-78-7, Fluoxetine hydrochloride 99300-78-4, Venlafaxine
hydrochloride 155270-99-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(medicinal compns. containing adenosine A2A receptor
antagonists and other
antidepressants)

L11 5 S L8 AND L9
L12 4 S L11 NOT L10
L13 1 S L12 AND (PY<2003 OR AY<2003 OR PRY<2003)

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Combination therapy including cyclooxygenase 2 (COX2) inhibitor(s)
for the
treatment of Parkinson's disease
ACCESSION NUMBER: 2003:855794 HCAPLUS Full-text
DOCUMENT NUMBER: 139:345938
TITLE: Combination therapy including cyclooxygenase 2
(COX2)
inhibitor(s) for the treatment of Parkinson's
disease
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.;
Maziasz,
Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

```
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   ----
----
     WO 2003088958        A2    20031030    WO 2003-US11269
20030414 <--
     WO 2003088958        A3    20040819
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA,
CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD,
GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR,
             LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO,
NZ, OM,
             PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN,
TR, TT,
             TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY,
             KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES,
             FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI,
SK, TR,
             BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
TD, TG
     CA 2481934           A1    20031030    CA 2003-2481934
20030414 <--
     AU 2003223579        A1    20031103    AU 2003-223579
20030414 <--
     US 20040034083       A1    20040219    US 2003-413348
20030414 <--
     EP 1494664           A2    20050112    EP 2003-719717
20030414 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE,
MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
     BR 2003009259        A     20050209    BR 2003-9259
20030414 <--
     JP 2005528403        T     20050922    JP 2003-585710
20030414 <--
     MX 2004009352        A     20050125    MX 2004-9352
20040924 <--
PRIORITY APPLN. INFO.:                       US 2002-373311P     P
20020418 <--
                                             WO 2003-US11269     W
20030414


               E KASE HIROSHI?/AU
L14         236 S E38
L15          15 S L14 AND L8
L16          15 S L15 AND (PY<2004 OR AY<2004 OR PRY<2004)
L17          14 S L16 NOT L10
L18         611 S SELECTIVE SEROTONIN REUPTAKE INHIBITORS/IT
L19           0 S L18 AND L8
L20          17 S L18 AND L3
```

L21 10 S L20 AND DEPRESSION?
L22 4 S L21 AND (PY<2004 OR AY<2004 OR PRY<2004)

L22 ANSWER 1 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Modified-release formulations of selective serotonin reuptake inhibitors
ACCESSION NUMBER: 2009:769895 HCAPLUS Full-text
DOCUMENT NUMBER: 151:86724
TITLE: Modified-release formulations of selective serotonin
reuptake inhibitors
INVENTOR(S): Maes, Paul J.; Muhuri, Goutam
PATENT ASSIGNEE(S): Biovail Laboratories Incorporated, Barbados
SOURCE: Can., 178pp.
CODEN: CAXXA4
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
CA 2415154	C	20090616	CA 2002-2415154	20021224 <--
CA 2415154	A1	20040624		
WO 2004058229	A1	20040715	WO 2003-CA1986	20031219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003292927	A1	20040722	AU 2003-292927	20031219 <--
EP 1633329	A1	20060315	EP 2003-788728	20031219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
US 20080138411	A1	20080612	US 2007-556492	20070606 <--

PRIORITY APPLN. INFO.: CA 2002-2415154 A

20021224 <--

WO 2003-CA1986 W

20031219 <--

L22 ANSWER 2 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Modified-release formulations of selective serotonin reuptake inhibitors
ACCESSION NUMBER: 2004:565069 HCAPLUS Full-text
DOCUMENT NUMBER: 141:111573
TITLE: Modified-release formulations of selective serotonin reuptake inhibitors
INVENTOR(S): Maes, Paul Jose; Muhuri, Goutam
PATENT ASSIGNEE(S): Biovail Laboratories Inc., Barbados
SOURCE: PCT Int. Appl., 214 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058229	A1	20040715	WO 2003-CA1986	20031219 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2415154	C	20090616	CA 2002-2415154	20021224 <--
CA 2415154	A1	20040624		
AU 2003292927	A1	20040722	AU 2003-292927	20031219 <--
EP 1633329	A1	20060315	EP 2003-788728	20031219 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				

L22 ANSWER 3 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Treatment of antidepressant drug-induced sexual dysfunction with apomorphine
ACCESSION NUMBER: 2002:505409 HCAPLUS Full-text
DOCUMENT NUMBER: 137:57597
TITLE: Treatment of antidepressant drug-induced sexual dysfunction with apomorphine
INVENTOR(S): Ruff, Dustin D.; Perdok, Renee J.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 6 pp., Cont. of U. S. Ser. No. 713,741, abandoned.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020086876	A1	20020704	US 2001-974136	20011010 <--
PRIORITY APPLN. INFO.:			US 2000-713741	B1 20001115 <--

IC ICM A61K031-4748
INCL 514295000
CC 1-12 (Pharmacology)
IT Mental and behavioral disorders
(depression; apomorphine for treatment of antidepressant-induced sexual dysfunction)
IT Biological transport
(uptake, selective serotonin reuptake inhibitors; apomorphine for treatment of antidepressant-induced sexual dysfunction)
IT 56296-78-7, Prozac 78246-49-8, Paxil 79559-97-0, Zoloft
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(apomorphine for treatment of antidepressant-induced sexual dysfunction, and use with antiemetics)
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L22 ANSWER 4 OF 4 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. A randomized trial
ACCESSION NUMBER: 2001:916187 HCAPLUS Full-text
DOCUMENT NUMBER: 136:241510
TITLE: Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care. A randomized trial
AUTHOR(S): Kroenke, Kurt; West, Suzanne L.; Swindle,

Ralph;
Gilsenan, Alicia; Eckert, George J.; Dolor, Rowena;
Stang, Paul; Zhou, Xiao-Hua; Hays, Ron; Weinberger,
Morris
CORPORATE SOURCE: Regenstrief Inst. Health Care, Indianapolis, IN,
46202, USA
SOURCE: JAMA, the Journal of the American Medical Association
(2001), 286(23), 2947-2955
CODEN: JAMAAP; ISSN: 0098-7484
PUBLISHER: American Medical Association
DOCUMENT TYPE: Journal
LANGUAGE: English
CC 1-11 (Pharmacology)
IT Antidepressants
(selective serotonin reuptake
inhibitors (SSRIs); similar effectiveness of paroxetine,
fluoxetine, and sertraline in primary care)
IT 56296-78-7, Fluoxetine hydrochloride 61869-08-7, Paroxetine
79617-96-2, Sertraline
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(similar effectiveness of paroxetine, fluoxetine, and sertraline in
primary care)

L23 4 S L8 AND DEPRESSION?
L24 3 S L23 AND (PY<2004 OR AY<2004 OR PRY<2004)

L24 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Adenosine A2a receptor antagonists for the treatment of extrapyramidal
syndrome and other movement disorders
ACCESSION NUMBER: 2006:463565 HCAPLUS Full-text
DOCUMENT NUMBER: 144:460860
TITLE: Adenosine A2a receptor antagonists for the treatment
of extrapyramidal syndrome and other movement disorders
INVENTOR(S): Grzelak, Michael; Hunter, John; Pond, Annamarie;
Varty, Geoffrey
PATENT ASSIGNEE(S): Schering Corp., USA
SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S.
Ser. No. 738,906.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060106040	A1	20060518	US 2005-234644	20050923 <--
US 20040138235	A1	20040715	US 2003-738906	20031217 <--
US 7414058	B2	20080819		
CA 2510655	A1	20050519	CA 2003-2510655	20031217 <--
AU 2003304527	A1	20050526	AU 2003-304527	20031217 <--
EP 1578409	A1	20050928	EP 2003-818838	20031217 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003017436	A	20051116	BR 2003-17436	20031217 <--
JP 2006514697	T	20060511	JP 2005-510511	20031217 <--
NZ 540493	A	20080430	NZ 2003-540493	20031217 <--
CN 101310724	A	20081126	CN 2008-10136154	20031217 <--
MX 2005006790	A	20050908	MX 2005-6790	20050620 <--
US 20060128694	A1	20060615	US 2005-249796	20051013 <--
AU 2006294919	A1	20070405	AU 2006-294919	20060921
CA 2623040	A1	20070405	CA 2006-2623040	20060921
WO 2007038212	A1	20070405	WO 2006-US36864	20060921
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				

KG, KZ, MD, RU, TJ, TM
EP 1940408 A1 20080709 EP 2006-815125
20060921
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK,
TR, AL,
BA, HR, MK, RS
JP 2009508967 T 20090305 JP 2008-532393
20060921
ZA 2008002552 A 20090624 ZA 2008-2552
20080319
MX 2008004006 A 20080410 MX 2008-4006
20080324
CN 101312731 A 20081126 CN 2006-80043146
20080519
PRIORITY APPLN. INFO.: US 2002-435321P P
20021219 <--
US 2003-738906 A2
20031217 <--
CN 2003-80107087 A3
20031217 <--
WO 2003-US40456 W
20031217 <--
US 2005-234644 A2
20050923
WO 2006-US36864 W
20060921
OTHER SOURCE(S): MARPAT 144:460860
INCL 514263240; 514263340
CC 1-11 (Pharmacology)
IT Mental and behavioral disorders
(depression, dystonia from antidepressant use; adenosine A2a
receptor antagonists for treatment of extrapyramidal syndrome
and other
movement disorders)
IT 59-92-7, Levodopa, biological studies 322-35-0, Benserazide
7439-89-6D, Iron, salts 12794-10-4D, Benzodiazepine, derivs.
28860-95-9, Carbidopa 155270-99-8 377727-26-9
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(adenosine A2a receptor antagonists for treatment of
extrapyramidal
syndrome and other movement disorders)

L24 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Medicinal compositions containing adenosine A2A receptor
antagonists and
other antidepressants
ACCESSION NUMBER: 2005:99358 HCAPLUS Full-text
DOCUMENT NUMBER: 142:162694
TITLE: Medicinal compositions containing adenosine
A2A
receptor antagonists and other antidepressants
INVENTOR(S): Kase, Hiroshi; Kobayashi, Minoru; Shiozaki,
Shizuo;
Mori, Akihisa; Seno, Naoki

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan
SOURCE: PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009444	A1	20050203	WO 2004-JP10758	20040722 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2533117	A1	20050203	CA 2004-2533117	20040722 <--
EP 1655029	A1	20060510	EP 2004-748023	20040722 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
US 20060241102	A1	20061026	US 2006-565239	20060119 <--
NO 2006000958	A	20060425	NO 2006-958	20060227 <--
PRIORITY APPLN. INFO.:			JP 2003-201549 A	20030725 <--
			WO 2004-JP10758 W	20040722

IC ICM A61K031-52
ICS A61K031-137; A61K031-335; A61K031-343; A61K031-36; A61K031-38;
A61K031-381; A61K031-435; A61K031-496; A61K031-5375; A61K031-55;
A61K031-553; A61P025-24
CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1

IT Mental and behavioral disorders
(depression; medicinal compns. containing adenosine A2A receptor
antagonists and other antidepressants)
IT 56296-78-7, Fluoxetine hydrochloride 99300-78-4, Venlafaxine hydrochloride 155270-99-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medicinal compns. containing adenosine A2A receptor antagonists and other
antidepressants)
OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
TI KW-6002, Kyowa Hakko Kogyo
ACCESSION NUMBER: 2001:438063 HCAPLUS Full-text
DOCUMENT NUMBER: 136:193429
TITLE: KW-6002, Kyowa Hakko Kogyo
AUTHOR(S): Knutsen, Lars J. S.; Weiss, Scott M.
CORPORATE SOURCE: Vernalis Research Limited, Berkshire, RG41 5UA, UK
SOURCE: Current Opinion in Investigational Drugs (PharmaPress
Ltd.) (2001), 2(5), 668-673
CODEN: COIDAZ
PUBLISHER: PharmaPress Ltd.
DOCUMENT TYPE: Journal; General Review
LANGUAGE: English
CC 1-0 (Pharmacology)
IT 155270-99-8, KW-6002
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(KW-6002 for treatment of Parkinson's disease)
OS.CITING REF COUNT: 22 THERE ARE 22 CAPLUS RECORDS THAT CITE THIS
RECORD (22 CITINGS)
REFERENCE COUNT: 38 THERE ARE 38 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l24 ti abs 3

L24 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN
TI KW-6002, Kyowa Hakko Kogyo
AB A review. Kyowa Hakko is developing KW-6002, an adenosine A2A receptor antagonist, for the potential treatment of Parkinson's disease (PD). The company subsequently began evaluating the compound for depression, and in June 2000 initiated a phase II trial for this indication. Good results have been obtained in a

preclin. depression model and Kyowa Hakko hopes that KW-6002 will be representative of a new class of antidepressants. KW-6002 is undergoing phase II trials for PD in Japan and in Europe, including the UK. The drug is of particular interest due to the absence of the involuntary movement adverse effects characteristic of L-DOPA therapy. Roche was to codevelop KW-6002 with Kyowa in the US and Europe, but withdrew from the development of this drug in Apr. 1999. Kyowa will continue with the drug's development in the US. NDAs are estimated to be filed around the end of 2001 and the drug is expected to be launched in Western Europe during 2002. An NDA is expected to be filed in Japan approx. three to four years later than in Western Europe.

```
                E KOBAYASHI MINORU?/AU
L25         401 S E49-E50
L26           4 S L25 AND L8
L27           3 S L26 NOT L10
L28           3 S L27 NOT L24
                E SHIOZAKI SHIZUO?/AU
L29          49 S E61-E62
L30           8 S L29 AND L8
L31           7 S L30 NOT L10
L32           7 S L31 NOT L24
L33           7 S L32 AND (PY<2004 OR AY<2004 OR PRY<2004)
                E MORI AKIHISA?/AU
L34         187 S E73-E74
L35           6 S L34 AND (L8 OR L3)
L36           5 S L35 NOT L10
L37           4 S L36 AND (PY<2004 OR AY<2004 OR PRY<2004)
L38           3 S L37 NOT L33
                E SENO NAOKI?/AU
L39          37 S E85-E86
L40           4 S L39 AND (L8 OR L3)
L41           1 S L40 NOT (L10 OR L33)
```